- Home
- CLPR vs CRBU Comparison
CLPR vs CRBU Comparison
Compare CLPR & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | CRBU |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | 97 |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.2M | 48.5M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CLPR | CRBU |
|---|---|---|
| Price | $3.23 | $0.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 24.0K | ★ 3.8M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 11.52% | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,997,000.00 | N/A |
| Revenue This Year | $0.91 | $114.75 |
| Revenue Next Year | $2.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.82 | N/A |
| 52 Week Low | $2.69 | $0.41 |
| 52 Week High | $3.94 | $2.49 |
Technical Indicators
Market Signals| Indicator | CLPR | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 27.27 |
| Support Level | $3.09 | N/A |
| Resistance Level | $3.28 | $0.58 |
| Average True Range (ATR) | 0.15 | 0.04 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 33.33 | 13.25 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.